Navigation Links
The molecular mechanism of a diabetes vaccine revealed

A team of researchers led by Prof. Irun Cohen of the Weizmann Institute of ScienceImmunology Department has revealed the molecular mechanism of a vaccine for Type 1 diabetes. The new findings should help amplify the effectiveness of the vaccine, which is currently in advanced stages of clinical trials. Type 1 diabetes is an autoimmune disorder in which the immune system mistakenly attacks the body's own insulin-producing pancreatic cells, reducing and ultimately eliminating the production of insulin ?a hormone needed to convert sugar, starches, and other foods into energy.

Several years ago, Prof. Cohen and colleagues developed a vaccine that arrests the progression of Type 1 diabetes in laboratory animals. They had discovered that a particular protein called HSP60, or even only a small particular fragment of it ?the peptide designated p277 ?is able to shut down the autoimmune response causing this disorder. The vaccine is currently being tested in clinical trials in Europe and the United States, but its precise mechanism has until now been unknown.

"When translating these findings into a practical vaccine, we knew enough about the mechanism to understand that this protein is able to cause a decrease in the immune response, but how it actually works eluded us," says Cohen. In a paper published in the Journal of Clinical Investigation, the scientists have managed to identify the exact immune cells that p277 acts upon and its mechanism of action.

Autoimmune diseases occur when certain T cells in the immune system attack the body's own cells and tissues. The scientists discovered that p277 directs the activity of the immune system in two ways. First, the p277 peptide steps up the activities of a different type of T cell that regulates the amount of potentially harmful T cells available. In addition, T cells treated with p277 cause the delinquent T cells to secrete anti-inflammatory substances instead of the inflammation-causing ones that they u sually make which lead to autoimmune disease. This double action of the peptide weakens the damaging activities of the immune response further. The scientists also showed that in order to activate this response, p277 must be bound to the receptor TLR-2, which is found on the cell walls of the regulatory T cells.

"These findings are important, as it means that by identifying the molecular activity of p277 with such precision, we can copy nature's own system in regulating the immune system and therefore, help to boost the immune system in preventing the destruction of insulin-producing pancreatic cells," says Cohen.

Postdoctoral fellow Dr. Alexandra Zanin-Zhorov spearheaded the project; the other scientists participating in this study were: the late Prof. Ofer Lider, Dr. LioraCahalon, postdoctoral fellow Guy Tal, and Raanan Margalit.


'"/>

Source:American Committee for the Weizmann Institute of Science


Related biology news :

1. Scientists ID molecular switch in liver that triggers harmful effects of saturated and trans fats
2. Source of molecular triggers in cutaneous T cell lymphoma identified
3. Plants, animals share molecular growth mechanisms
4. NYU researchers simulate molecular biological clock
5. Scientists reveal molecular secrets of the malaria parasite
6. Scientists identify molecular events that drive cell senescence
7. Researchers discover molecular mechanism that desensitizes us to cold
8. Findings have implications for tracking disease, drugs at the molecular level
9. Successful Test Of Single Molecule Switch Opens The Door To Biomolecular Electronics
10. At the molecular level, the predator is the prey
11. By creating molecular bridge, scientists change function of a protein
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/18/2017)... 2017 MedNet Solutions , an ... entire spectrum of clinical research, is proud to ... for the organization in terms of corporate growth, ... products and services. The company,s exceptional achievements can ... iMedNet ™ – ...
(Date:1/11/2017)... DES MOINES, Iowa , Jan. 11, 2017 /PRNewswire/ ... another industry first with the release of its patent-pending ... to quickly and reliably perform calibrations, securely upload data ... more flexibility for the customer. "Fighting drunk ... not only for the public at large, but also ...
(Date:1/4/2017)... the thousands of attendees at this year,s International Consumer Electronics Show (CES), ... measurement devices and services, will be featuring its new line of ULTRA ... special CES Exhibit Suite , the new upper arm and wrist ... WellnessConnected product platform.  Continue Reading ... ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... GAITHERSBURG, Md. , Jan. 19, 2017 ... Inc., a privately-held immunotherapeutics company targeting infectious diseases, ... for the merger of PharmAthene and Altimmune in ... Venture Fund, HealthCap, Truffle Capital and Redmont Capital. ... diversified immunotherapeutics company with four clinical stage and ...
(Date:1/19/2017)... Staten Island, NY (PRWEB) , ... January 19, 2017 , ... ... expand at an exponential rate. The tremendous growth is accounted to two main ... to the table and the expanding network of vendors supplying FireflySci products all around ...
(Date:1/19/2017)... FRANKLIN LAKES, N.J. , Jan. 18, 2017 BD ... medical technology company, announced today that it will host a live ... 2017, at 1 p.m. (ET). The webcast can ... will be available for replay through Tuesday, January 31, 2017. ... About BD ...
(Date:1/18/2017)... 2017   Parent Project Muscular Dystrophy (PPMD) , ... Duchenne muscular dystrophy (Duchenne) , today announced a $600,000 ... of Technology (NJIT) and Talem Technologies (Talem) as part ... to assist people living with Duchenne. PPMD is ... an embedded computer, software, a force sensor and a ...
Breaking Biology Technology: